Datos a fecha 04/05/26 03:55
| Ticker | ACAN |
|---|---|
| ISIN | GB00BYWF9Y76 |
| Sector | Financiero |
| Industria | Biotechnology |
| Mercado | París |
| Beta | 1,79 |
| Sitio web | https://www.acaciapharma.com |
| CEO | Michael Bolinder |
| Fecha de IPO | 05/03/2018 |
| País | GB |
| Dirección | The Officers Mess Business Centre, Royston Road, Cambridge, CB22 4QH |
| Volumen | 761.376 |
Acacia Pharma Group plc discovers, develops, and commercializes pharmaceutical products for the patients undergoing surgery, invasive procedures, or chemotherapy treatments in the United States and internationally. The company's lead product is BARHEMSYS, an intravenous amisulpride for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also include BYFAVO, an intravenous remimazolam and reversible IV sedative designed for use during invasive medical procedures, ...
El precio actual de Acanthe Developpement SE (ACAN) es de 0,89 , con una variación del 0,00%.
Acanthe Developpement SE opera en el sector Healthcare, industria Biotechnology.
Compara brokers con acceso a las principales bolsas internacionales, con bajas comisiones, custodia y herramientas de análisis para invertir en acciones.
Compara brokers para acciones